Cambridge Executive Breakfast

Bridge Laboratories and China Preclinical Management Services are hosting a complimentary breakfast presentation discussing why a sizable and growing number of western pharmaceutical companies are placing preclinical safety studies in China.

You may not know that many pharmaceutical companies are now leveraging capabilities in China for far more than just chemistry outsourcing and clinical trials.
Perhaps the area of greatest opportunity, particularly for small and mid-size biopharmas, is the availability of high quality preclinical development services. The preclinical CRO sector in China has rapidly evolved and expanded, such that there is now significant capacity with a demonstrated track record of working to western standards and meeting western regulatory expectations.

Based on China Preclinical Management Services’ (CPMS) rigorous evaluation of preclinical CROs in China and Bridge Laboratories’ experience as a preclinical services provider in China, the following observations have been made:

Preclinical capabilities in China can now be leveraged by small and mid-size biopharmas for substantial benefit including cost and speed.
China’s CRO sector has greatly matured, and presently many CROs offer robust global standard preclinical capabilities. None of you can take a chance on quality, and it has reached the point where this is no longer an issue for many types of studies.
The challenge for small and mid-size biopharmas is to determine which partners to work with in China and for which studies.

Please join us as China Preclinical Management Services and Bridge Laboratories share insights into the current status and trends of the China preclinical safety sector and how companies like yours may be able to leverage it. As part of the discussion, Bridge Laboratories, which is among the leading and most established "western standard" CROs in China, will discuss their experience conducting GLP toxicology studies for companies across the country.

Cambridge Executive Breakfast

Date:	November 6, 2008
Breakfast & Networking:	7:00am — 8:00am
Presentation and Q&A:	8:00am — 9:00am
Location:	Boston Cambridge Marriott Hotel
	Two Cambridge Center Cambridge, MA
Cost:	Free

To register for the event, please click here.

Who is China Preclinical Management Services (CPMS)?

CPMS was spun out of Cambridge Healthtech Associates (CHA) to assist western and Chinese biotech and pharmaceutical companies to leverage US FDA/OECD GLP compliant safety facilities in China. China Preclinical Management Services is headquartered and incorporated in the United States with personnel both in the U.S. and China. The Mission of CPMS is to support the industry in improving the economics of developing new drugs by taking full advantage Global Standard preclinical development resources in China

Who is Bridge Laboratories?

Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory compliant drug development services globally. Bridge is US-owned and is headquartered in Gaithersburg, Maryland, with lab facilities in the US and Beijing, China. Bridge is known for its extensive work in toxicology; including a wide variety of in vivo toxicology studies that examine the effect on the immune system, vaccines, developmental and reproductive toxicology, and safety pharmacology. Bridge’s AAALAC accredited facility in China was among the first labs to perform GLP studies for clients worldwide.